Clinical Trials Logo

Panic Disorder clinical trials

View clinical trials related to Panic Disorder.

Filter by:

NCT ID: NCT00634790 Terminated - Panic Disorder Clinical Trials

A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks

Start date: May 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the long-term safety and tolerability of alprazolam extended release (XR) in adolescents with panic disorder, with or without agoraphobia, or in anxiety disorder with panic attacks. Efficacy, population pharmacokinetics of alprazolam XR and the relationship between alprazolam XR plasma concentrations and efficacy outcomes will also be evaluated.

NCT ID: NCT00322803 Terminated - Panic Disorder Clinical Trials

ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment

Start date: May 2006
Phase: Phase 2
Study type: Interventional

This study is designed to investigate if 600 mg ELB139 given orally t.i.d. to patients suffering from panic disorder is effective in reducing anxiety evoked by inhalation of 35% CO2 measured by a visual analogue scale after the first intake and after approximately one week of treatment as compared to placebo treatment.

NCT ID: NCT00206765 Terminated - Panic Disorder Clinical Trials

Risperidone vs. Paroxetine for Panic Attacks

Start date: January 2003
Phase: Phase 2
Study type: Interventional

We are comparing the efficacy of Risperidone versus Paroxetine in the treatment of panic symptoms. The study hypothesis is that Risperidone will be a superior medicine for treating panic.

NCT ID: NCT00182533 Terminated - Clinical trials for Major Depressive Disorder

Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders

Start date: July 2002
Phase: Phase 4
Study type: Interventional

Selective serotonin reuptake inhibitors (SSRIs) including sertraline have been found to be effective in the treatment of generalized social phobia (GSP). However, virtually all of the current treatment studies with medicines, including the SSRIs, have excluded patients with social phobia who have other co-occurring conditions. In fact, 80% of individuals suffering with primary social phobia have at least one other anxiety. This study will evaluate the safety and efficacy of sertraline in the treatment of generalized social phobia with co-occurring anxiety and mood disorders.